Milestone Pharmaceuticals MIST 深 滬
已收盤 02-06 16:00:00 美东时间
1.76
+0.040
+2.33%
華盛通- 最 高1.80
- 今 開1.75
- 成交量 162.36万股
- 最 低 1.745
- 昨 收 1.72
- 總市值 1.50亿
- 52周最高 3.06
- 市盈率 靜 --
- 換手率 1.91%
- 52周最低 0.6254
- 委 比 96.18%
- 總股本 8516.93万
- 歷史最高 27.95
- 量 比 0.60
- 振 幅 3.20%
- 歷史最低 0.6254
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Inc. granted 419,000 stock options to two new employees under its 2021 Inducement Plan. The options, with a February 2, 2026 grant date and $1.96 exercise price, vest over four years. The award aligns with Nasdaq Listing Rule 5635(c)(4), applicable to non-employee hires. Milestone is a biopharmaceutical company focused on innovative cardiovascular treatments, including CARDAMYST™ for heart condition management.
02-03 13:00
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
An update from Milestone Pharmaceuticals ( ($MIST) ) is now available. On Janua...
01-26 22:51
Milestone Pharmaceuticals Announces Availability Of Cardamyst (Etripamil) Nasal Spray, Its First Commercial Product, Through US Retail Pharmacies
CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Implementation of a rapid commercialization
01-26 21:05
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals announced the availability of CARDAMYST™ (etripamil) nasal spray through U.S. retail pharmacies. The FDA-approved treatment for paroxysmal supraventricular tachycardia (PSVT) in adults is supported by a national sales force launching mid-February and a patient assistance program offering copay caps at $25 for eligible insured patients.
01-26 13:00
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Milestone Pharmaceuticals announced the acceptance of its Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for etripamil nasal spray, a novel treatment for paroxysmal supraventricular tachycardia (PSVT). Etripamil, conditionally approved as TACHYMIST™ in Europe, is a self-administered nasal spray for PSVT outside healthcare settings. A decision on approval is expected by Q1 2027. The MAA submission is supported by ...
01-06 13:00
美股机会日报 | AI“循环交易”再现？OpenAI寻求亚马逊100亿美元投资；美股年内最大IPO今夜挂牌上市
AI“循环交易”再现？OpenAI寻求亚马逊100亿美元投资；美股今年最大IPO诞生，Medline今夜挂牌上市；Robotaxi利好引爆，特斯拉股价重回巅峰>>
2025-12-17 21:09
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target
TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and announces $8 price target.
2025-12-16 00:34
